Eli Lilly Reports Topline Data from P-III (SURMOUNT-1) Trial of Tirzepatide to Treat Type 2 Diabetes
Shots:
- The P-III (SURMOUNT-1) trial assessed Tirzepatide (5mg, 10mg or 15mg) vs PBO to treat patients (n=1032) with type 2 diabetes with pre-diabetes and obesity or overweight of 176 wks., followed by 17 wks. without treatment, making a total of 193 weeks.
- The study showed a 94% reduced risk of progression to type 2 diabetes. The 2EPs were also reached, showing 15.4%, 19.9%, 22.9% vs 2.1% (efficacy estimand) & 12.3%, 18.7%, 19.7% vs 1.3% (treatment-regimen estimand) reduced body wt.
- This data primary analysis at 72 weeks was published in the NEJM in 2022
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
